The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
3 | 1 | 3 | 15 |
Growth
|
85 | 91 | 99 | 71 |
Safety
|
47 | 51 | 57 | 33 |
Sentiment
|
66 | 91 | 63 | 47 |
|
60 | 69 | 67 | 23 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
97 | 100 | 100 | 97 |
Opinions Change
|
10 | 97 | 50 | 50 |
Pro Holdings
|
n/a | 90 | 45 | 4 |
Market Pulse
|
91 | 30 | 21 | 39 |
Sentiment
|
66 | 91 | 63 | 47 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
3 | 1 | 3 | 15 |
Growth
|
85 | 91 | 99 | 71 |
|
47 | 51 | 57 | 33 |
Combined
|
32 | 39 | 61 | 11 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
13 | 7 | 31 | 43 |
Price vs. Earnings (P/E)
|
9 | 7 | 1 | 6 |
Price vs. Book (P/B)
|
15 | 10 | 19 | 28 |
Dividend Yield
|
8 | 1 | 1 | 23 |
Value
|
3 | 1 | 3 | 15 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
96 | 100 | 91 | 60 |
Profit Growth
|
98 | 92 | 44 | 42 |
Capital Growth
|
52 | 9 | 87 | 98 |
Stock Returns
|
43 | 100 | 83 | 39 |
Growth
|
85 | 91 | 99 | 71 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
48 | 76 | 72 | 50 |
Refinancing
|
5 | 24 | 34 | 26 |
Liquidity
|
58 | 60 | 76 | 57 |
|
47 | 51 | 57 | 33 |
Discover high‑ranked alternatives to Cohance Lifesciences and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.